The Oncotype DX^® test provides significant value in clinical practice

The Oncotype DX Breast Recurrence Score^® result is predictive of chemotherapy benefit in your postmenopausal patients with HR+, HER2-, node-positive (1-3 positive nodes), early-stage, invasive breast cancer as demonstrated by the SWOG-8814 study.¹ Data from SWOG-8814 and the RxPONDER randomized prospective trial show that a substantial proportion of these patients can be spared chemotherapy.^1,7

CT benefit expressed in percentage points based on probability of distant recurrence (N0) or distant recurrence-free interval (N1) with/without CT at 5 years. No CT benefit is considered for an absolute benefit <1%.
*The benefit of chemotherapy for premenopausal N1 patients with RS^® results 26-100 has not been formally assessed in a randomized study. The benefit derived from chemotherapy was significant for RS^® results 0-13 and 14-25 in the RxPONDER study and it is inferred to be substantial for patients with RS^® 26-100.

Use of the Oncotype DX test may reduce the risk of overtreatment with chemotherapy in node-positive HR+, HER2- early-stage breast cancer^1,6-7

Average chemotherapy treatment rates without genomic testing are in the range of 70% for this patient population^8-9. RxPONDER demonstrated that many of these patients may be overtreated^6-7, and the Oncotype DX test can help make informed treatment decisions.

N1

Nodal status, despite being of prognostic value, does not predict the Recurrence Score result and the underlying tumour biology⁴

CLINICAL UTILITY OF THE ONCOTYPE DX ASSAY

In summary, adjuvant chemotherapy may be guided with the Oncotype DX test to identify the majority of node-positive patients (with up to 3 positive nodes) who will not benefit from the addition of chemotherapy.^1,6-7